• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research >Safety assessment of the butyrate-producing Butyricicoccus pullicaecorum strain 25-3(T), a potential probiotic for patients with inflammatory bowel disease, based on oral toxicity tests and whole genome sequencing
【24h】

Safety assessment of the butyrate-producing Butyricicoccus pullicaecorum strain 25-3(T), a potential probiotic for patients with inflammatory bowel disease, based on oral toxicity tests and whole genome sequencing

机译：生产丁酸丁酸丁酸丁酸丁基菌菌株25-3（T）的安全评估，炎症性肠病患者的潜在益生菌，基于口腔毒性测试和全基因组测序

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Inflammatory bowel disease (IBD) is a chronic inflammation of the digestive tract, characterized by dysbiosis of the intestinal microbiota. Probiotics have been suggested as a strategy to reduce active disease or extend remission. We isolated and characterized the butyrate-producing strain Butyricicoccus pullicaecorum 25-3(T) and identified it as a potential probiotic for patients with IBD. To evaluate the safety of 25-3(T) for use in humans, we conducted a standard acute oral toxicity test and a 28-day repeated oral dose toxicity test. The complete genome of B. pullicaecorum 25-3(T) was sequenced to search for virulence factors and antibiotic resistance determinants. The minimum inhibitory concentration (MIC) of 21 antimicrobials was determined. Results showed no adverse effects in the oral toxicity tests. B. pullicaecorum 25-3(T) is resistant against aminoglycosides and trimethoprim. The genome of 25-3(T) contains no virulence factors, one gene related to harmful metabolites and 52 sequences with high similarity to antimicrobial and toxic compound resistance genes, that did not correspond with a resistant phenotype. This first report of a safety assessment of a butyrate-producing strain from Clostridium cluster IV shows that B. pullicaecorum 25-3(T) is a non-pathogenic strain, but carries antibiotic resistance genes with the risk of transfer, that need further investigation. (C) 2014 Elsevier Ltd. All rights reserved.
机译：炎症性肠病（IBD）是消化道的慢性炎症，其特征在于肠道微生物群的脱敏病。已经提出益生菌作为减少活跃疾病或延长缓解的策略。我们分离并表征了产生的丁酸菌株诱导的菌株PullicaCorum 25-3（T），并将其作为IBD患者的潜在益生菌鉴定为潜在的益生菌。为了评估用于人类的25-3（T）的安全性，我们进行了标准的急性口服毒性测试，并进行了28天的重复口服剂量毒性试验。对B. pullicaecorum 25-3（t）的完整基因组进行测序，以寻找毒力因子和抗生素抗性决定簇。确定21例抗微生物的最小抑制浓度（MIC）。结果表明口腔毒性试验中没有不利影响。 B. PullicaEcorum 25-3（T）对氨基糖苷和三甲硅烷酯耐药。 25-3（T）的基因组含有无毒因子，一种与有害代谢物和52个序列有关的一个基因，与抗微生物和有毒复合抗性基因具有高相似性，其与耐药表型不相对应。从梭菌簇IV的产生丁酸盐菌株的安全评估的第一个报告表明，B. pullicaCorum 25-3（t）是一种非致病菌菌株，但携带抗生素抗性基因，具有进一步调查的转移风险，需要进一步调查。 （c）2014年elestvier有限公司保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号